A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
A phase 1/2 trial of Azacitidine in chronic myelomonocytic leukaemia and mds/mpn overlap neoplasms, run by Treadwell Therapeutics, Inc, active and no longer recruiting.
Overview
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML is a phase 1/2 interventional study registered as NCT04730258 by Treadwell Therapeutics, Inc, with 72 participants planned, started 2021-04-16 and due to reach its primary completion in 2026-01. Interventions recorded: CFI-400945, Azacitidine. Conditions listed: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine.
- TrialStudy to Evaluate the Safety and Tolerability of EP0042
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine.
- TrialA Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine.
- TargetDNMT1 (DNA methyltransferase 1)
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine.
- TrialClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine.
- TermHypomethylating agents (azacitidine, decitabine)
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine.
- CancerSystemic mastocytosis
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine.
- PathwayEpigenetic reprogramming
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine.